Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134789

Published: 2020

Journal Articles

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Blood (2020) 136 (Supplement 1): 19–22.

https://doi.org/10.1182/blood-2020-134676

Published: 2020

Journal Articles

Treatment Patterns and Healthcare Resource Utilization in Patients with Multiple Myeloma and Baseline Renal Impairment

Parameswaran Hari, MD MRCP, Lita Araujo, Dominick Latremouille-Viau, MSc, Peggy Lin, PhD, Mikhail Davidson, Annie Guerin, MSc, Medha Sasane

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-134597

Published: 2020

Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Ehab L. Atallah, MD, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Carmine Rossi, PhD, Annie Guerin, MSc, Pallavi Patwardhan, PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-136074

Published: 2020

Journal Articles

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Eytan M. Stein, MD, Dominick Latremouille-Viau, George J Joseph, Sherry Shi, Annie Guerin, MSc, Eric Q Wu, Gaetano Bonifacio, Xiting Cao

Blood (2019) 134 (Supplement_1): 3495.

https://doi.org/10.1182/blood-2019-124878

Published: 2019

Journal Articles

Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study

Blood (2019) 134 (Supplement_1): 3048.

https://doi.org/10.1182/blood-2019-131401

Published: 2019

Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Eytan M. Stein, MD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Sherry Shi, MSc, Patrick Gagnon-Sanschagrin, BSc, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD

Blood (2016) 128 (22): 5929.

https://doi.org/10.1182/blood.V128.22.5929.5929

Published: 2016

Journal Articles

Short-Term and Long-Term Economic Burden Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adult Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Richard T. Maziarz, MD, Yanni Hao, PhD, Annie Guerin, MSc, Genevieve Gauthier, MSc, Marjolaine Gauthier-Loiselle, PhD, Simu K Thomas, PhD, Lamis K Eldjerou, MD

Blood (2016) 128 (22): 5933.

https://doi.org/10.1182/blood.V128.22.5933.5933

Published: 2016

Journal Articles

Reduction in Healthcare Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia (CML) with Better Adherence to Tyrosine Kinase Inhibitors (TKIs) and Increased Molecular Monitoring Frequency

Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Patrick Gagnon-Sanschagrin, BSc, Katherine Dea, MSc, Benjamin Cohen, MPH, George J Joseph, BPharm, MS, PhD

Blood (2016) 128 (22): 2398.

https://doi.org/10.1182/blood.V128.22.2398.2398

Published: 2016

Journal Articles

Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

Nanxin Li, Chelsey Yang, Liangyi Fan, Todor Totev, Annie Guerin, MSc, Lei Chen, MDPhD

Blood (2015) 126 (23): 2090.

https://doi.org/10.1182/blood.V126.23.2090.2090

Published: 2015

Journal Articles

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Annie Guerin, MSc, Saurabh Ray, PhD, Genevieve Gauthier, MSc, Ling-I Hsu, PhD, Maryia Zhdanava, Eric Wu, PhD

Blood (2015) 126 (23): 3313.

https://doi.org/10.1182/blood.V126.23.3313.3313

Published: 2015

Journal Articles

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Richard T. Maziarz, MD, Annie Guerin, MSc, Genevieve Gauthier, MSc, Julie Heroux, MSc, Maryia Zhdanava, MSc, Eric Q Wu, PhD, Simu K Thomas, PhD, Lei Chen, MDPhD

Blood (2015) 126 (23): 872.

https://doi.org/10.1182/blood.V126.23.872.872

Published: 2015

Journal Articles

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Lei Chen, MD PhD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Roy Nitulescu, MSc, Patrick Gagnon-Sanschagrin, BSc

Blood (2015) 126 (23): 1596.

https://doi.org/10.1182/blood.V126.23.1596.1596

Published: 2015

Journal Articles

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

B. Douglas Smith, MD, Jun Liu, PhD, Dominick Latremouille-Viau, MSc, Zhou Zhou, MSc, Annie Guerin, MSc, Daniel Fernandez, MA, Dingdong Yi, BS, Xufei Wang, MA, Eric Q Wu, PhD, Shivani K Mhatre, MSc, Christopher H Keir, MD, Lei Chen, MD PhD

Blood (2014) 124 (21): 2618.

https://doi.org/10.1182/blood.V124.21.2618.2618

Published: 2014

Journal Articles

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

Blood (2014) 124 (21): 1293.

https://doi.org/10.1182/blood.V124.21.1293.1293

Published: 2014

Journal Articles

Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Annie Guerin, MSc, Cindy Revol, MPH, Agnihotram V. Ramanakumar, PhD, Rebekah Foster, BA, Eric Qiong Wu, PhD, Shivani K Mhatre, MSc, Lei Chen, MD PhD

Blood (2014) 124 (21): 1304.

https://doi.org/10.1182/blood.V124.21.1304.1304

Published: 2014

Journal Articles

Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up

Lei Chen, MD, PhD, Annie Guerin, MSc, Maryna Marynchenko, MBA, Raluca Ionescu-Ittu, PhD, Robert Hiscock, MSc, Roy Nitulescu, MA, Chopra Pooja, MSc, Ling-I Hsu, MPH, Christopher Keir, MD, Eric Qiong Wu, PhD

Blood (2013) 122 (21): 4038.

https://doi.org/10.1182/blood.V122.21.4038.4038

Published: 2013

Journal Articles

Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.

Daniel J. DeAngelo, MD, PhD, Lei Chen, MD, PhD, Annie Guerin, MSc, Amy Styles, MSc, Clemence Aberki, BSc, Philippe Giguere-Duval, BSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 2792.

https://doi.org/10.1182/blood.V120.21.2792.2792

Published: 2012

Journal Articles

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

James D. Griffin, MD, Annie Guerin, MSc, Lei Chen, MD, PhD, Alexander R. Macalalad, MD, Jiayuan Luo, MSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 2796.

https://doi.org/10.1182/blood.V120.21.2796.2796

Published: 2012

Journal Articles

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Stuart L. Goldberg, MD, Lei Chen, MD, PhD, Solveig G. Ericson, MD, PhD, Alexander R. Macalalad, MD, Annie Guerin, MSc, Nathan Liu, MPH, Michael Kaminsky, BSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 1685.

https://doi.org/10.1182/blood.V120.21.1685.1685

Published: 2012

NARROW

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Treatment Patterns and Healthcare Resource Utilization in Patients with Multiple Myeloma and Baseline Renal Impairment

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Short-Term and Long-Term Economic Burden Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adult Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Reduction in Healthcare Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia (CML) with Better Adherence to Tyrosine Kinase Inhibitors (TKIs) and Increased Molecular Monitoring Frequency

Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up

Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only